Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 15,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Peripartum Cardiomyopathy, Cardiogenic Shock
Interventions: Clinical placement of a temporary IMPELLA® mechanical circulatory support device.; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
Interventions: Nicotinamide riboside; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 35 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Coronary Artery Disease
Interventions: Dabigatran, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Medication Non-adherence
Interventions: SMS (Text messages); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Grand Rapids, Michigan

Conditions: Multiple Myeloma
Interventions: AMG 224; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: West Hollywood, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Hypertension
Interventions: Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cardiovascular Risk Factor
Interventions: Spice blend; Other
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Interventions: Elotuzumab, Lenalidomide, Questionnaire Administration; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Peripheral Neuropathy, Diabetic Foot Ulcer
Interventions: Orpyx Sensory Insole System; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Menlo Park, California • San Francisco, California • San Rafael, California + 15 more

Conditions: Ischemic Brain Injury, Stroke, Healthy Individual, Patent Foramen Ovale (PFO), Neurovascular Injury
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions: The Angel® Catheter; Device
Lead sponsor: BiO2 Medical; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions: anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Coronary Artery Disease
Interventions: FFR-guided PCI, CABG; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: COPD, Emphysema, Emphysema or COPD
Interventions: dual anti-platelet therapy, Placebo; Combination Product · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Digital Coaching Plan, Health Awareness; Behavioral
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Lipoprotein Disorder
Interventions: LY3473329, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio

Conditions: Orthostatic Hypotension
Interventions: Midodrine, Intravenous fluid bolus; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Daratumumab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Peripheral Artery Disease, Intermittent Claudication
Interventions: ALD-301, Placebo (vehicle); Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 40 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Stanford, California • Gainesville, Florida • Miami, Florida + 5 more

Conditions: Insomnia, Insomnia Chronic, Insomnia, Primary, Sleep Disturbance, Sleep Disorder, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke, Autonomic Dysfunction, Systemic Inflammatory Response, Metabolic Disease
Interventions: Sleep Healthy Using The Internet (SHUTi), Telephonic CBT-I, Face-to-Face CBT-I, Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care; Behavioral · Other
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Coagulation; Intravascular
Interventions: Protamine fixed dose, Protamine ratio dose; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Dexamethasone, Carfilzomib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Palm Springs, California • Riverside, California • Glenwood Springs, Colorado + 26 more

Search by objective public record fields.

PPCM Observational Study (Peripartum Cardiomyopathy)

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Chlorthalidone and HCTZ Impacts on Platelet Activation

The Effect of Spice Consumption on Postprandial Vascular Function

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Wearable Insoles for Recurrent Diabetic Ulcer Prevention

A Study of Patients With AIDS Syndrome

Clinical Proteomic Research for the Brain

The Angel® Catheter Pivotal Clinical Trial

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Breathing-Induced Myocardial Oxygenation Reserve

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended

Anti-Platelets in Chronic Obstructive Pulmonary Disease

Investigating Behavior Change Methods for the Management of Hypertension

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Patients With Intermittent Claudication Injected With ALDH Bright Cells

SHADES Mechanistic Trial

Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers